High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults.
暂无分享,去创建一个
A Engert | G. Schwarzer | J. Bohlius | A. Engert | A Greb | J Bohlius | D Schiefer | G Schwarzer | H Schulz | H. Schulz | D. Schiefer | A. Greb
[1] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[2] T. Molina,et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Barbui,et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[5] T. Numbenjapon,et al. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. , 2000, Clinical lymphoma.
[6] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.
[7] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[9] E. Gehan,et al. Combined cyclophosphamide, vincristine, and prednisone therapy of malignant lymphoma , 1971, Cancer.
[10] P. Richardson,et al. The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses , 1999, Bone Marrow Transplantation.
[11] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Karen A Robinson,et al. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.
[13] A. Melnyk,et al. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[14] J. Vose,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[15] T. Chisesi,et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Armitage,et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Hollis,et al. What is meant by intention to treat analysis? Survey of published randomised controlled trials , 1999, BMJ.
[18] N. Schmitz,et al. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingd , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Hagenbeek,et al. A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. , 2003, The hematology journal : the official journal of the European Haematology Association.
[20] T. Molina,et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. , 2003, Blood.
[21] J. Vose,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin's lymphoma. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] T. Grogan,et al. The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. , 1988, Blood.
[23] A. Zelenetz,et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. , 2000, Blood.
[24] D. Neuberg,et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Hagenbeek,et al. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). , 1995, Bone marrow transplantation.
[26] L F Burmeister,et al. A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage. , 1995, JAMA.
[27] R. Schilsky. End points in cancer clinical trials and the drug approval process. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] J. Matthews,et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Parmar,et al. Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.
[30] A. Pileri,et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.
[31] M. Parmar,et al. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.
[32] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. , 2004, Blood.
[33] A. Nademanee,et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. , 1997, Blood.
[34] Dirk Hasenclever,et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. , 2004, Blood.
[35] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[36] P. Gaulard,et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] T. Barbui,et al. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high international prognostic index (IPI). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] N. Schmitz,et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] F. Gherlinzoni,et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A R Jadad,et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. , 1995, Controlled clinical trials.
[41] R. Gressin,et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. , 2004, The New England journal of medicine.
[42] R. Fanin,et al. Autologous stem cell transplantation for aggressive non-Hodgkin’s lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index , 1998, Bone Marrow Transplantation.
[44] L. Gordon,et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. , 1992, The New England journal of medicine.
[45] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[46] P. Martiat,et al. A quantitative study of peripheral blood stem cell contamination in diffuse large‐cell non‐Hodgkin's lymphoma: one‐half of patients significantly mobilize malignant cells , 2000, British journal of haematology.
[47] P. Gaulard,et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). , 1998, Blood.
[48] S. Pileri,et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] M. Buyse,et al. Issues of efficiency in combining proportions of deaths from several clinical trials. , 1987, Statistics in medicine.
[50] J. Pignon,et al. Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. , 2001, Controlled clinical trials.
[51] H. Kluin-Nelemans,et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. , 2001, Journal of the National Cancer Institute.
[52] F. Berger,et al. Original article: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen , 1990 .
[53] C Sebban,et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). , 2000, Blood.
[54] E. Deconinck,et al. Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial , 2000, British journal of haematology.
[55] T. Intragumtornchai,et al. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. , 2003, Clinical lymphoma.
[56] D C Linch,et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] K. Dickersin,et al. Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .
[58] W Hiddemann,et al. Lymphoma classification--the gap between biology and clinical management is closing. , 1996, Blood.
[59] T. Chisesi,et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] Douglas G Altman,et al. Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.
[61] E. Greenspan. Clinical interpretation and practice of cancer chemotherapy , 1982 .
[62] E. Frei,et al. Chemotherapy of malignant lymphoma with adriamycin. , 1973, Cancer research.
[63] J. Raemaekers,et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[64] G. Morgan,et al. Autologous stem cell transplantation for malignancy: a systematic review of the literature. , 2000, Clinical and laboratory haematology.
[65] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[66] B. Coiffier,et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] H. Vet,et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. , 1998, Journal of clinical epidemiology.
[68] L. Norton,et al. The Norton-Simon hypothesis revisited. , 1986, Cancer treatment reports.
[69] George Davey Smith,et al. meta-analysis bias in location and selection of studies , 1998 .
[70] C. Mayr,et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. , 2003, Haematologica.
[71] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[72] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[73] R. Fisher. Treatment of aggressive non‐hodgkin's lymphomas: Lessons from the past 10 years , 1994 .
[74] P. Gaulard,et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.